Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Flow cytometry–based cytotoxicity assay. Determination of Dato-DXd and control ADC IC₅₀ (mean SEM) in the tested cell lines. A, Cell line with 0 TROP2 expression [i.e., END(K)34] showed no difference in the IC₅₀ of Dato-DXd and control ADC. B and C, Cell lines with high TROP2 expression [3+; i.e., END(K)254 and END(K)265] demonstrated significantly lower IC₅₀ for Dato-DXd when compared with control ADC (P < 0.05)